Medical progress: Primary biliary cirrhosis

New England Journal of Medicine

Volumn 335, Issue 21, 1996, Pages 1570-1580

  Kaplan, Marshall M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CIMETIDINE; COLCHICINE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; GLUCOCORTICOID; METHYLTESTOSTERONE; MITOCHONDRION ANTIBODY; NALOXONE; PENICILLAMINE; PHENOBARBITAL; PREDNISOLONE; PREDNISONE; RIFAMPICIN; URSODEOXYCHOLIC ACID; METHOTREXATE;

BILIARY CIRRHOSIS; CLINICAL TRIAL; HUMAN; HUMORAL IMMUNITY; HYPOTHYROIDISM; LIVER BIOPSY; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; STEATORRHEA; ULTRAVIOLET B RADIATION; IMMUNOLOGY; LIVER; LIVER MITOCHONDRION; PATHOLOGY; PROGNOSIS;

COLCHICINE; CYCLOSPORINE; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; METHOTREXATE; MITOCHONDRIA, LIVER; PROGNOSIS; URSODEOXYCHOLIC ACID;

EID: 0030597246     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199611213352107     Document Type: Review

References (153)

1. Myszor M, James OF. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med 1990;75: 377-85.
2. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1987;316:521-8.
3. Watson RG, Angus PW, Dewar M, Goss B, Sewell RB, Smallwood RA. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Gut 1995;36:927-30.
4. Danielsson A, Boqvist L, Uddenfeldt P Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 1990;11:458-64.
5. Villeneuve J-P, Fenyves D, Infante-Rivard C. Descriptive epidemiology of primary biliary cirrhosis in the province of Quebec. Clin Gastroenterol 1991;5:174-8.
6. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994; 20:698-701.
7. James SP, Jones EA, Schafer DF, Hoofnagle JH, Varma RR, Strober W. Selective immunoglobulin A deficiency associated with primary biliary cirrhosis in a family with liver disease. Gastroenterology 1986;90:283-8.
8. Galbraith RM, Smith M, Mackenzie RM, Tee DE, Doniach D, Williams R. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 1974;290:63-9.
9. Schaffner F. Primary biliary cirrhosis. Clin Gastroenterol 1975;4:351-66.
10. Tong MJ, Nies KM, Reynolds TB, Quismorio FP. Immunological studies in familial primary biliary cirrhosis. Gastroenterology 1976;71:305-7.
11. Miller KB, Sepersky RA, Brown KM, Goldberg MJ, Kaplan MM. Genetic abnormalities of immunoregulation in primary biliary cirrhosis. Am J Med 1983;75:75-80.
12. Caldwell SH, Leung PS, Spivey JR, et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 1992;16:899-905.
13. Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992;16:1404-8.
14. Gregory WL, Mehal W, Dunn AN, et al. Primary biliary cirrhosis: contribution of HLA class II allele DR8. Q J Med 1993;86:393-9.
15. Mella JG, Roschmann E, Maier KP, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. Hepatology 1995;21:398-402.
16. Underhill JA, Donaldson PT, Doherty DG, Manabc K, Williams R. HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 1995;21:959-62.
17. Summerfield JA, Elias E, Hungerford GD, Nikapota VL, Dick R, Sherlock S. The biliary system in primary biliary cirrhosis: a study by endoscopic retrograde cholangiopancrcatography. Gastroenterology 1976,70:240-3.
18. Colina. F, Pinedo F, Solis JA, Moreno D, Nevado M. Nodular regen-erative hyperplasia of the liver in early, hisrcological stages of primary biliary cirrhosis. Gastroenterology 1992;102:1319-24.
19. Outwater E, Kaplan MM, Bankoff MS. Lymphadenopathy in primary biliary cirrhosis: CT observations. Radiology 1989;171:731-3.
20. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967;60:1257-60.
21. Ludwig J. New concepts in biliary cirrhosis. Semin Liver Dis 1987;7: 293-301.
22. Hashimoto E, Lindor KD, Homburger HA, et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc 1993;68:1049-55.
23. Nakanuma Y. Distribution of B lymphocytes in nonsuppurative cholangitis in primary biliary cirrhosis. Hepatology 1993;18:570-5.
24. Mocbius U, Manns M, Hess G, Kober G, Meyer zum Buschenfelde KH, Meuer SC. T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones. Eur J Immunol 1990; 20:889-96.
25. MacSwecn RN, Burt AD. The cellular pathology of primary biliary cirrhosis. Mol Aspects Med 1985;8:269-91.
26. Colucci G, Schaffner F, Paronetto F. In situ characterization of the cell-surface antigens of the mononuclcar cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol 1986;41:35-42.
27. Yasoshima M, Nakanuma Y, Tsuneyama K, Van de Water J, Gershwin ME. Immunohistochernical analysis or adhesion molecules in the microenvironment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol 1995; 175:319-25.
28. Van de Water J, Turchany J, Leung PS, et al. Molecular mimicry in primary biliary cirrhosis: evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993;91:2653-64.
29. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985;88:1777-90.
30. MacSween RN. Mallory's ('alcoholic') hyaline in primary biliary cirrhosis. J Clin Pathol 1973;26:340-2.
31. Vaux DJ, Watt F, Grime GW, Takacs J. Hepatic copper distribution in primary biliary cirrhosis shown by the scanning protein microprobE. J Clin Pathol 1985;38:653-8.
32. Kowdley KV, Knox TA, Kaplan MM. Hepatic copper content is normal in early primary biliary cirrhosis and primary sclerosing cholangitis. Dig Dis Sci 1994;39:2416-20.
33. Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 1991;100:822-33.
34. James SP, Hoofnagle JH, Strober W, Jones EA. Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 1983;99:500-12.
35. Lindgren S, Eriksson S. IgM in primary biliary cirrhosis: physicochemical and complement activating properties. J Lab Clin Med 1982;99:636-45.
36. Nouri-Aria KT, Hegarty JE, Neuberger J, Eddleston AL, Williams R. In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis. Clin Exp Immunol 1985;61:297-304.
37. Thomas HC, Holden R, Jones JV, Peacock DB. Immune response to phi X 174 in man. 5. Primary and secondary antibody production in primary biliary cirrhosis. Gut 1976;17:844-8.
38. Lindgren S, Johnson U. Complement activation in primary biliary cirrhosis: an in vitro model. J Lab Clin Med 1985;105:432-5.
39. James SP, Jones EA, Hoofnagle JH, Strober W. Circulating activated B cells in primary biliary cirrhosis. J Clin Immunol 1985;5:254-60.
40. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982;57:365-70.
41. Roberts-Thomson PJ, Shepherd K. Low molecular weight IgM in primary biliary cirrhosis. Gut 1990;31:88-91.
42. Fakunle YM, Aranguibel F, de Villiers D, Thomas HC, Sherlock S. Monomeric (7S) IgM in chronic liver disease. Clin Exp Immunol 1979;38: 204-10.
43. Minuk GY, Boyd ND, Matheson DS, Fritzler MJ, Green BJ. Serum immunoglobulin E levels in patients with primary biliary cirrhosis. J Allergy Clin Immunol 1989;83:462-6.
44. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965;1:827-31.
45. Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989;320;1377-80.
46. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210. J Exp Med 1995;182:1159-62.
47. Elra GH, Sepersky RA, Goldberg MJ, Connors CM, Miller KB, Kaplan MM. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dig Sci 1983;28:971-5.
48. Pares A, Martorell J, Caballeria J, Vives J, Brugucra M, Rodes J. Lymphocytotoxic antibodies in primary biliary cirrhosis. Dig Dis Sci 1985;30: 829-33.
49. Sundewall AC, Lefvert AK, Olsson R. Anti-acetylcholine receptor antibodies in primary biliary cirrhosis. Acta Med Scand 1985;217:519-25.
50. Bassendine MF, Collins JD, Stephenson J, Saunders P, James OF. Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia? Gut 1985;26:1074-9.
51. Penner E. Demonstration of immune complexes containing the ribonucleoprotein antigen Ro in primary biliary cirrhosis. Gastroenterology 1986;90:724-7.
52. Penner E, Muller S, Zimmermann D, Van Regenmortel MH. High prevalence of antibodies to histones among patients with primary biliary cirrhosis. Clin Exp Immunol 1987;70:47-52.
53. Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunotluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995;10: 438-45.
54. Goldberg MJ, Kaplan MM, Mitamura T, et al. Evidence against an immune complex pathogenesis of primary biliary cirrhosis. Gastrocntcrology 1982;83:677-83.
55. Miller KB, Elta GH, Rudders RA, Kaplan MM. Lymphocyte subsets in primary biliary cirrhosis. Ann Intern Med 1984;100:385-7.
56. James SP, Elson CO, Waggoner JG, Jones EA, Strober W. Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis. J Clin Invest 1980;66:1305-10.
57. Moreno-Otero R, Civeira MP, Suou T, Kanof ME, James SP, Jones EA. Reduced numbers of CD8+ T cells and B cell-expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis. Hepatogastroenterology 1994;41:239-43.
58. Suou T, Civeira MP, Kanof ME, Moreno-Otero R, Jones EA, James SP. Detective immunoregulation in primary biliary cirrhosis: CD4+, Leu-8+ T cells have abnormal activation and suppressor function in vitro. Hepatology 1989;10:408-13.
59. Menendez JL, Giron JA, Manzano L, et al. Deficient interleukin-2 responsiveness of T lymphocytes from patients with primary biliary cirrhosis. Hepatology 1992;16:931-6.
60. Spengler U, Moller A, Jung MC, et al. T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxins, tumor necrosis factor and Interferon-gamma upon mitogen stimulation. J Hepatol 1992;15:129-35.
61. Van de Water J, Ansari AA, Surh CD, et al. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991;146:89-94.
62. Jones DE, Palmer JM, James OF, Yeaman SJ, Bassendine MF, Diamond AG. T-cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology 1995;21:995-1002.
63. Miyamoto T, Maeda T, Onishi S, Yamamoto Y. T cell autoreactivity against a 28 kD biliary protein (B1-p28) in primary biliary cirrhosis. J Hepatol 1995;22:423-30.
64. Coppel RL, McNeilage LJ, Surh CD, et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A 1988;85:7317-21.
65. Van de Water J, Fregeau D, Davis P, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988;141:2321-4.
66. Davis PA, Leung P, Manns M, et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 1992;16:1128-36.
67. Palmer JM, Yeaman SJ, Bassendine MF, James OF. M4 and M9 autoantigens in primary biliary cirrhosis - a negative study. J Hepatol 1993;18: 251-4.
68. Krams SM, Surh CD, Coppel RL, Ansari A, Ruebner B, Gershwin ME. Immunization of experimental animals with dihydrolipoamide acetyl-transferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989;9:411-6.
69. Fussey SP, Bassendine MF, James OF, Yeaman SJ. Characterisation of the reactivity of autoantibodies in primary biliary cirrhosis. FEBS Lett 1989;246:49-53.
70. Kaplan MM, Rabson AR, Lee Y-M, Williams DL, Montaperto PA. Discordant occurrence of primary biliary cirrhosis in monozygotic twins. N Engl J Med 1994;331:952.
71. D'Amico E, Paroli M, Fratelli V, et al. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995;40:2113-6.
72. Moradpour D, Altorfer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20:1437-41.
73. Tsuneyama K, Van de Water J, Leung PS, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histoeompatibility complex class II and BB1/B7 expression. Hepatology 1995;21:1031-7.
74. Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, de Vries RA, Brandt KH. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth J Med 1992;41:11-6.
75. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more Hydrophobic bile salts: in vitro studies in rat hepatocytes and human crythrocyres. Hepatology 1991;14:920-6.
76. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973;289:674-8.
77. Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977;72:1204-7.
78. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study. Gastroenterology 1990;98:1567-71.
79. Tornay AS Jr. Primary biliary cirrhosis: natural history. Am J Gastroenrerol 1980;73:223-6.
80. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 1977;73:1125-30.
81. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9.
82. Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 1994;89:1840-3.
83. Christensen E, Crowo J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980;78:236-46.
84. Fleming CR, Dickson ER, Hollenhorst RW, Goldstein NP, McCall JT, Baggenstoss AH. Pigmented corneal rings in a patient with primary biliary cirrhosis. Gastroenterology 1975;69:220-5.
85. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7.
86. Ahrens EJ Jr, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. Medicine (Baltimore) 1950;29:299-364.
87. Iannuzzi C, Cozzolino G, Negro G. Elective cholecystectomy in selected cirrhotic patients. Acta Chir Belg 1993;93:147-50.
88. Jahn CE, Schacfer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis: association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985;89:1266-78.
89. Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesteroleniia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992;15:858-62.
90. Gregory WL, Game FL, Farrer M, Idle JR, Laker MF, James OF. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 1994;105:43-50.
91. Simon JR, Poon RW. Lipoprotein-X levels in extrahepatic versus intrahepatic cholestasis. Gastroenterology 1978;75:177-80.
92. Poupon RE, Ougucrram K, Chretien Y, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993;17:577-82.
93. Poupon RE, Balkau B, Guechot J, Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994;19:635-40.
94. Olornu AB, Vickers CR, Waring RH, et al. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med 1988; 318:1089-92.
95. Davics MH, Ngong JM, Pean A, Vickers CR, Waring RH, Elias E. Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis. J Hepatol 1995;22:551-60.
96. Ros E, Garcia-Puges A, Reixach M, Cuso E, Rodes J. Fat digestion and exocrine pancreatic function in primary biliary cirrhosis. Gastroenterology 1984;87:180-7.
97. Lanspa SJ, Chan AT, Bell JS III, Go VL, Dickson ER, DiMagno EP. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology 1985; 5:837-42.
98. Reynolds TB, Denison EK, Frankl HD, Lieberman FL, Peters RL. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia: new syndrome. Am J Med 1971;50:302-12.
99. Tsianos EV, Hoofnagle JH, Fox PC, et al. Sjogren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990;11:730-4.
100. Giovannini A, Ballardini G, Amatetti S, Bonazzoli P, Bianchi FB. Patterns of lacrimal dysfunction in primary biliary cirrhosis. Br J Ophthalmol 1985;69:832-5.
101. Schussler GC, Schaffner F, Korn F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med 1978;299:510-5.
102. Pares A, Rimola A, Bruguera M, Mas E, Rodes J. Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology 1981;80:681-6.
103. Loof L, Adami HO, Sparen P, et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. Hepatology 1994;20: 101-4.
104. Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990;12:98-105.
105. Butler P, Hamilton-Miller JM, McIntyre N, Burroughs AK. Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut 1995;36:931-4.
106. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982;83:97-102.
107. Kaplan MM, Goldberg MJ, Matloff DS, Neer RM, Goudman DB. Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis. Gastroenterology 1981;81:681-5.
108. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995;95:2581-6.
109. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982;83:103-8.
110. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995;21:389-92.
111. Camisasca M, Crosignani A, Battezzati PM, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994;20:633-7.
112. Guanabens N, Pares A, del Rio L, et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992;15:345-9.
113. Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988;95: 787-92.
114. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:707-13.
115. Dickson ER, Fleming TR, Wiesner RH, et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985;312:1011-5.
116. Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis: clinicopathoiogic and serologic correlations in 200 cases. Dig Dis Sci 1995;40:1232-42.
117. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis: a progress report on long term follow-up and natural history. Gastroenterology 1985;89:267-71.
118. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985;89:1084-91.
119. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7.
120. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-80.
121. Poupon RE, Poupon R, Balkau B, UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
122. Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26:291-4.
123. Thornton JR, Triger DR, Losowsky MS. Variccal bleeding is associated with reduced risk of severe cholestasis in primary biliary cirrhosis. Q J Med 1989;71:467-71.
124. Navasa M, Pares A, Bruguera M, Caballeria J, Bosch J, Rodes J. Portal hypertension in primary biliary cirrhosis: relationship with histological features. J Hepatol 1987;5:292-8.
125. Boyer TD, Kokenes DD, Hertzler G, Kutner MH, Henderson JM. Effect of distal splenorenal shunt on survival of patients with primary biliary cirrhosis. Hepatology 1994;20:1482-6.
126. Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworrhy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10:846-50.
127. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled triai of prednisolone treatment in primary biliary cirrhosis: three-year results. J Hepatol 1992;15:336-44.
128. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
129. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
130. Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66.
131. Heathcote EJ, Lindor KD, Poupon R, et al. Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1995; 108:Suppl:A1082. abstract.
132. Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterisation of patients With a complete biochemical response to ursodeoxycholic acid. Gut 1995;36:935-8.
133. Wiesner RH, Ludwig J, Lindor KD, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322:1419-24.
134. Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993;104:519-26.
135. Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicinc for primary biliary cirrhosis. N Engl J Med 1986;315:1448-54.
136. Bodenheimer HC Jr, Schaffner F, Sternlieb I, Klion FM, Vernace S, Pezzullo J. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985;5:1139-42.
137. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis: trial design and preliminary report. J Hepatol 1987;5:1-7.
138. Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991;14:990-3.
139. Vuoristo M, Farkkila M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995;108:1470-8.
140. Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J Gastrocnterol Hepatol 1992;7:277-82.
141. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991;101:1332-8.
142. Kaplan MM. Sustained remission of primary biliary cirrhosis (PBC) with methotrexate (MTX). Gastroenterology 1995;108:Suppl:A1094. abstract.
143. Kaplan M, Schmid C, McKusick A, Provenzale D, Sharma A, Sepe T. Double-blind trial of methotrexate (MTX) versus colchicine (COLGH) in primary biliary cirrhosis (PBC). Hepatology 1993;18:Suppl:176A. abstract.
144. Kaplan MM, Dickstein G, Schmid C. Methotrexate (MTX) improves histology in primary biliary cirrhosis (PBC). Hepatology 1994;20:Suppl: 152A. abstract.
145. Miller LC, Sharma A, McKusick AF, Tassoni JP, Dinarello CA, Kaplan MM. Synthesis of interleukin-1 beta in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression. Hepatology 1995;22:518-24.
146. Kaplan MM. The therapeutic effects, of ursodiol and methotrexate are additive and well tolerated in primary biliary cirrhosis (PBC). Hepatology 1992;16:Suppl:92A. abstract.
147. Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol 1993; 18:9-14.
148. Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995;22:1158-62.
149. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994;107:266-70.
150. Markus BH, Dickson ER, Grambsch PM, et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1709-13.
151. Gouw AS, Haagsma EB, Manns M, Klompmaker IJ, Slooff MJ, Gerber MA. Is there recurrence of primary biliary cirrhosis after liver transplantation? A clinicopathologic study in long-term survivors. J Hepatol 1994; 20:500-7.
152. Balan V, Bans KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993;18:1392-8.
153. Kaplan MM. Primary biliary cirrhosis - a first step in prolonging survival. N Engl J Med 1994;330:1386-7.